Abstract
Design of inhibitors of P-glycoprotein still represents a challenging task for medicinal chemists. The polyspecificity of the transporter combined with the limited structural information renders rational drug design approaches rather ineffective. Within this article we will exemplify how recent insights into structure and mechanism of Pglycoprotein may aid in design of potent inhibitors. P >
Keywords: Cyclic peptide P-glycoprotein inhibitor, ATP-binding cassette, Nucleotide binding domain, Transmembrane domain, Central nervous system, Blood brain barrier, Breast cancer related protein, Positron emission tomography, Single-photon emission computed tomography, Cytochrome P450-3A4, Multidrug resistance, MDR, Protein-ligand interaction fingerprints, Serotonine reuptake transporter, Dopamine transporter, Norepinephrine transporter, Structure activity relationship, Radiolabeled P-gp substrates, SAV1866, Ligand docking, Quinazolinones, GABAA receptor, Pharmacophore modeling, NCI-60 screening, ATPbinding site, Tyrosine kinases (TKs), Nilotinib, Dasatinib, Bosutinib, ATPases
Current Topics in Medicinal Chemistry
Title: Using Structural and Mechanistic Information to Design Novel Inhibitors/Substrates of P-Glycoprotein
Volume: 10 Issue: 17
Author(s): Freya Klepsch, Thomas Stockner, Thomas Erker, Markus Muller, Peter Chiba and Gerhard F. Ecker
Affiliation:
Keywords: Cyclic peptide P-glycoprotein inhibitor, ATP-binding cassette, Nucleotide binding domain, Transmembrane domain, Central nervous system, Blood brain barrier, Breast cancer related protein, Positron emission tomography, Single-photon emission computed tomography, Cytochrome P450-3A4, Multidrug resistance, MDR, Protein-ligand interaction fingerprints, Serotonine reuptake transporter, Dopamine transporter, Norepinephrine transporter, Structure activity relationship, Radiolabeled P-gp substrates, SAV1866, Ligand docking, Quinazolinones, GABAA receptor, Pharmacophore modeling, NCI-60 screening, ATPbinding site, Tyrosine kinases (TKs), Nilotinib, Dasatinib, Bosutinib, ATPases
Abstract: Design of inhibitors of P-glycoprotein still represents a challenging task for medicinal chemists. The polyspecificity of the transporter combined with the limited structural information renders rational drug design approaches rather ineffective. Within this article we will exemplify how recent insights into structure and mechanism of Pglycoprotein may aid in design of potent inhibitors. P >
Export Options
About this article
Cite this article as:
Klepsch Freya, Stockner Thomas, Erker Thomas, Muller Markus, Chiba Peter and F. Ecker Gerhard, Using Structural and Mechanistic Information to Design Novel Inhibitors/Substrates of P-Glycoprotein, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792928004
DOI https://dx.doi.org/10.2174/156802610792928004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Updates of Chemically Modified Electrodes in Pharmaceutical Analysis
Combinatorial Chemistry & High Throughput Screening Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials
Current Drug Targets Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry New Therapies for Sepsis
Current Topics in Medicinal Chemistry Advances in the Synthesis of Calystegines and Related Products and their Biochemical Properties
Mini-Reviews in Medicinal Chemistry Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice
Current Vascular Pharmacology Ruptured Renal Artery Aneurysm: Successful Endovascular Therapy with Stent-Graft Placement
Current Medical Imaging Neurokinin-1 (NK<sub>1</sub>) receptor antagonists as possible therapeutics for psychostimulant use disorders
CNS & Neurological Disorders - Drug Targets Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Development of Calorie Restriction Mimetics as Therapeutics for Obesity, Diabetes, Inflammatory and Neurodegenerative Diseases
Current Genomics Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine